GHRP-6: The Pioneering Growth Hormone Releasing Peptide
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that was among the first growth hormone secretagogues developed, playing a foundational role in the discovery of the ghrelin receptor and the ghrelin signaling system. Developed by Cyril Bowers in the 1980s, GHRP-6 demonstrated that a receptor system independent of GHRH could stimulate growth hormone release from the pituitary — a discovery that ultimately led to the identification of ghrelin in 1999 (Bowers et al., 1984; Kojima et al., 1999).
GHRP-6 remains one of the most studied GH secretagogues in research, with a published literature spanning nearly four decades.
Molecular Profile
- Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
- Amino acids: 6 (hexapeptide with D-amino acid modifications)
- Molecular weight: ~873.0 Da
- CAS number: 87616-84-0
- Receptor target: GHSR1a (growth hormone secretagogue receptor / ghrelin receptor)
- D-amino acids: D-Trp at position 2 and D-Phe at position 5 confer protease resistance
- Half-life: ~15-60 minutes
Mechanism of Action
GHRP-6 binds to the growth hormone secretagogue receptor type 1a (GHSR1a) on anterior pituitary somatotrophs. This receptor was initially characterized as the "GHRP receptor" before being identified as the ghrelin receptor after ghrelin's discovery (Howard et al., 1996):
- Pituitary GH release: GHSR1a activation increases intracellular calcium in somatotrophs, triggering GH granule release via a phospholipase C-dependent mechanism
- Hypothalamic signaling: GHRP-6 also acts centrally to stimulate GHRH neurons and suppress somatostatin release, amplifying the GH pulse
- GHRH synergy: The GHRP pathway is synergistic with GHRH, producing amplified GH releases when administered together
- Appetite stimulation: GHSR1a activation in the hypothalamus and vagal afferents stimulates appetite and food intake
Research Area 1: Growth Hormone Secretion
Bowers et al. (1984) first demonstrated that synthetic enkephalin analogs could stimulate GH release, leading to GHRP-6's development as a specific GH secretagogue. The peptide reliably stimulates GH release in a dose-dependent manner across species, including humans, and was instrumental in establishing the existence of a GH-releasing pathway separate from GHRH.
Bowers et al. (1990) subsequently demonstrated the powerful synergistic effect between GHRP-6 and GHRH. When co-administered, the two compounds produced GH releases that exceeded the sum of either compound alone, confirming that they activated distinct but complementary signaling mechanisms on somatotroph cells.
Research Area 2: Cardiac Protection
GHRP-6 has demonstrated direct cardioprotective effects independent of GH secretion. Berlanga et al. (2007) showed that GHRP-6 reduced myocardial infarct size in a rat ischemia-reperfusion model, with protective effects that were not blocked by GH receptor antagonists — indicating a direct cardiac mechanism rather than GH-mediated protection.
The cardioprotective mechanism has been linked to activation of the PI3K/Akt survival pathway and reduction of pro-apoptotic signaling in cardiomyocytes during ischemic stress. Marleau et al. (2006) confirmed that GHRP analogs including GHRP-6 demonstrated anti-atherogenic properties, suggesting cardiovascular benefits beyond acute cardioprotection.
Research Area 3: Appetite and Metabolic Regulation
GHRP-6's activation of the ghrelin receptor produces notable appetite stimulation. Arvat et al. (2001) documented significant increases in hunger scores and food intake following GHRP-6 administration in clinical studies. This appetite-stimulating effect has made GHRP-6 a tool for studying orexigenic (appetite-promoting) pathways.
The appetite effects are mechanistically interesting because they provided early evidence that the GHSR1a receptor served dual functions — regulating both GH secretion and energy homeostasis — a concept that was later confirmed when ghrelin was identified as the endogenous ligand.
Research Area 4: Gastric Motility and GI Function
GHRP-6 has been studied for effects on gastrointestinal motility, consistent with ghrelin's known role as a prokinetic hormone. Trudel et al. (2002) demonstrated that GHRP-6 stimulated gastric motility and accelerated gastric emptying in animal models, mediated through vagal afferent activation and direct effects on GI smooth muscle.
These GI effects have positioned GHRP-6 as a research tool in gastroparesis and post-surgical ileus models, where impaired gastric motility is a clinical concern.
Research Area 5: Pituitary Function Testing
GHRP-6 has been extensively studied as a diagnostic tool for pituitary GH reserve. Popovic et al. (2000) demonstrated that the combined GHRP-6 + GHRH test was the most potent and reliable stimulus for GH secretion, providing a robust diagnostic tool for distinguishing GH deficiency from normal pituitary function.
This diagnostic application has been validated across multiple clinical studies and age groups, establishing the GHRP-6/GHRH combination test as a reference standard in some clinical centers for GH deficiency evaluation.
Current Research Status
GHRP-6 holds historical significance as the peptide that revealed the ghrelin receptor system and pioneered the field of GH secretagogues. Its well-characterized pharmacology, established research safety profile, and extensive published literature make it a benchmark compound in GH axis research. While newer, more selective compounds have been developed, GHRP-6 remains widely used in preclinical research.
Research Disclaimer
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.